Volume 4, Issue 1, January 2016, Page: 1-15
Melanoma Review: Epidemiology, Risk Factors, Diagnosis and Staging
Rodrigo Arrangoiz, Sociedad Quirúrgica S.C. at the American British Cowdray Medical Center, Mexico City, Mexico
Joel Dorantes, Sociedad Quirúrgica S.C. at the American British Cowdray Medical Center, Mexico City, Mexico
Fernando Cordera, Sociedad Quirúrgica S.C. at the American British Cowdray Medical Center, Mexico City, Mexico
Manuel Muñoz Juarez, Sociedad Quirúrgica S.C. at the American British Cowdray Medical Center, Mexico City, Mexico
Eduardo Moreno Paquentin, Sociedad Quirúrgica S.C. at the American British Cowdray Medical Center, Mexico City, Mexico
Enrique Luque de León, Sociedad Quirúrgica S.C. at the American British Cowdray Medical Center, Mexico City, Mexico
Received: Feb. 22, 2016;       Accepted: Mar. 8, 2016;       Published: Apr. 21, 2016
DOI: 10.11648/j.jctr.20160401.11      View  10259      Downloads  937
Abstract
Study Aim: Cutaneous melanoma accounts for approximately 4% of all skin cancers diagnosis each year in the USA but is responsible for 75% of skin cancer deaths. Physicians need to have an up to date knowledge about the epidemiology, risk factors, and clinical features of melanoma in order to make an early diagnosis and provide appropriate management decisions to improve survival in this aggressive malignancy. We will be presenting an extensive, up to date, literature review of cutaneous melanoma including the epidemiology, risk factors, diagnosis and staging. Method: An extensive literature review was performed using the following search engines: Pubmed, Ovid, Miromedex, and Dynamed. We limited our literature search to research papers written in English using the following keywords: cutaneous melanoma, epidemiology of melanoma, risk factors for melanoma, diagnosis of melanoma, clinical classification and staging of melanoma. Results: As a result of our extensive literature review we present an up to date review on the epidemiology, pathogenesis, risk factors, diagnosis, classification and staging of cutaneous melanoma. Conclusion: Physicians need to have an up to date knowledge about the epidemiology, risk factors, and clinical features in order to make an early diagnosis and provide appropriate management decisions in order to improve the survival patients with this aggressive malignancy.
Keywords
Cutaneous Melanoma, Epidemiology of Melanoma, Risk Factors for Melanoma, Diagnosis of Melanoma, Clinical Classification and Staging of Melanoma
To cite this article
Rodrigo Arrangoiz, Joel Dorantes, Fernando Cordera, Manuel Muñoz Juarez, Eduardo Moreno Paquentin, Enrique Luque de León, Melanoma Review: Epidemiology, Risk Factors, Diagnosis and Staging, Journal of Cancer Treatment and Research. Vol. 4, No. 1, 2016, pp. 1-15. doi: 10.11648/j.jctr.20160401.11
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Siegel, R., et al., Cancer statistics, 2014. CA Cancer J Clin, 2014. 64(1): p. 9-29.
[2]
Cancer Facts and Figures 2015., in American Cancer Society. 2015, American Cancer Society: Atlanta.
[3]
Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2014. CA Cancer J Clin, 2014. 63(1): p. 11-30.
[4]
Jemal, A., et al., Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol, 2011. 65(5 Suppl 1): p. S17-25 e1-3.
[5]
Sheets, S. S. F., Melanoma of the Skin. 2013.
[6]
Society, A. C., Cancer Facts and Figures 2013.
[7]
Edwards, B. K., et al., Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer, 2013.
[8]
Parkin, D. M., D. Mesher, and P. Sasieni, 13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer, 2011. 105 Suppl 2: p. S66-9.
[9]
Robinson, J. K., Sun exposure, sun protection, and vitamin D. JAMA, 2005. 294(12): p. 1541-3.
[10]
Rigel, D. S., J. Russak, and R. Friedman, The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin, 2010. 60(5): p. 301-16.
[11]
Desmond, R. A. and S. J. Soong, Epidemiology of malignant melanoma. Surg Clin North Am, 2003. 83(1): p. 1-29.
[12]
Greenlee, R. T., et al., Cancer statistics, 2001. CA Cancer J Clin, 2001. 51(1): p. 15-36.
[13]
Ries LA, E. M., Kosary CL, et al., SEER Cancer Statistics Review, 1973-1999. 2002: Bethesda, Maryland.
[14]
Surveillance, E., and End Results Program 1975-2004, FIve Year Survival Rates Based on Follow up of Patients Through 2004, D.o.C.C.a.P. Sciences, Editor. 2007: National Cancer Institute.
[15]
Ries LAG, M. D., Krapcho, M, et al. (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), N. C. Institute, Editor. 2004: Bethesda, MD.
[16]
Thompson, J. F., R. A. Scolyer, and R. F. Kefford, Cutaneous melanoma. Lancet, 2005. 365(9460): p. 687-701.
[17]
Pfeifer, G. P., Y. H. You, and A. Besaratinia, Mutations induced by ultraviolet light. Mutat Res, 2005. 571(1-2): p. 19-31.
[18]
Pfeifer, G. P. and A. Besaratinia, UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci, 2012. 11(1): p. 90-7.
[19]
Cogliano, V. J., et al., Preventable exposures associated with human cancers. J Natl Cancer Inst, 2011. 103(24): p. 1827-39.
[20]
Cancer, I. A. f. R. o., Solar and ultraviolet radiation. Monographs on the Evaluation of Carcinogenic Risks to Humans. 1992, Lyon: IARCPress.
[21]
Dennis, L. K., et al., Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis. Ann Epidemiol, 2008. 18(8): p. 614-27.
[22]
Neale, R. E., et al., Site-specific occurrence of nonmelanoma skin cancers in patients with cutaneous melanoma. Br J Cancer, 2005. 93(5): p. 597-601.
[23]
Zanetti, R., et al., Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer, 2006. 94(5): p. 743-51.
[24]
Nelemans, P. J., et al., An addition to the controversy on sunlight exposure and melanoma risk: a meta-analytical approach. J Clin Epidemiol, 1995. 48(11): p. 1331-42.
[25]
Elwood, J. M. and J. Jopson, Melanoma and sun exposure: an overview of published studies. Int J Cancer, 1997. 73(2): p. 198-203.
[26]
Gandini, S., et al., Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer, 2005. 41(14): p. 2040-59.
[27]
Scherer, D. and R. Kumar, Genetics of pigmentation in skin cancer--a review. Mutat Res, 2010. 705(2): p. 141-53.
[28]
Fitzpatrick, T. B., The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol, 1988. 124(6): p. 869-71.
[29]
Pelucchi, C., et al., Risk factors for histological types and anatomic sites of cutaneous basal-cell carcinoma: an italian case-control study. J Invest Dermatol, 2007. 127(4): p. 935-44.
[30]
Gallagher, R. P., et al., Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol, 1995. 131(2): p. 157-63.
[31]
Olsen, C. M., H. J. Carroll, and D. C. Whiteman, Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer, 2010. 127(10): p. 2430-45.
[32]
Williams, P. F., et al., Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer, 2011. 129(7): p. 1730-40.
[33]
Bauer, J. and C. Garbe, Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res, 2003. 16(3): p. 297-306.
[34]
Gerstenblith, M. R., et al., Basal cell carcinoma and anthropometric factors in the U.S. radiologic technologists cohort study. Int J Cancer, 2012. 131(2): p. E149-55.
[35]
Gerstenblith, M. R., J. Shi, and M. T. Landi, Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res, 2010. 23(5): p. 587-606.
[36]
Ting, W. H., et al., Clinical and laboratory characteristics of type 1 diabetes in children and adolescents: experience from a medical center. Acta Paediatr Taiwan, 2007. 48(3): p. 119-24.
[37]
Kiiski, V., et al., Risk factors for single and multiple basal cell carcinomas. Arch Dermatol, 2010. 146(8): p. 848-55.
[38]
Lachiewicz, A. M., et al., Epidemiologic support for melanoma heterogeneity using the Surveillance, Epidemiology, and End Results Program. J Invest Dermatol, 2008. 128(1): p. 243-5.
[39]
Little, E. G. and M. J. Eide, Update on the current state of melanoma incidence. Dermatol Clin, 2012. 30(3): p. 355-61.
[40]
Ting, W., et al., Tanning bed exposure increases the risk of malignant melanoma. Int J Dermatol, 2007. 46(12): p. 1253-7.
[41]
Monograph, S. A., Cancer Epidemiology in Older Adolescentes and Young Adults. 2007: p. 53-57.
[42]
Linos, E., et al., Increasing burden of melanoma in the United States. J Invest Dermatol, 2009. 129(7): p. 1666-74.
[43]
El Ghissassi, F., et al., A review of human carcinogens--part D: radiation. Lancet Oncol, 2009. 10(8): p. 751-2.
[44]
Wehner, M. R., et al., Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ, 2012. 345: p. e5909.
[45]
Kwon, H. T., et al., Promotion of frequent tanning sessions by indoor tanning facilities: two studies. J Am Acad Dermatol, 2002. 46(5): p. 700-5.
[46]
Demierre, M. F., Time for the national legislation of indoor tanning to protect minors. Arch Dermatol, 2003. 139(4): p. 520-4.
[47]
Boniol, M., et al., Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ, 2012. 345: p. e4757.
[48]
BA., G., Skin and aging process. CRC Press., 1984. 124.
[49]
Abbasi, N. R., et al., Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA, 2004. 292(22): p. 2771-6.
[50]
Rhodes, A. R., et al., Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA, 1987. 258(21): p. 3146-54.
[51]
Dulon, M., et al., Sun exposure and number of nevi in 5- to 6-year-old European children. J Clin Epidemiol, 2002. 55(11): p. 1075-81.
[52]
Wachsmuth, R. C., et al., Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol, 2001. 117(2): p. 348-52.
[53]
Tsao, H., M. B. Atkins, and A. J. Sober, Management of cutaneous melanoma. N Engl J Med, 2004. 351(10): p. 998-1012.
[54]
Gandini, S., et al., Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer, 2005. 41(1): p. 28-44.
[55]
Olsen, C. M., H. J. Carroll, and D. C. Whiteman, Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila), 2010. 3(2): p. 233-45.
[56]
Greene, M. H., et al., High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med, 1985. 102(4): p. 458-65.
[57]
Reimer, R. R., et al., Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA, 1978. 239(8): p. 744-6.
[58]
Clark, W. H., Jr., et al., Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol, 1978. 114(5): p. 732-8.
[59]
Lynch, H. T., T. G. Shaw, and J. F. Lynch, Inherited predisposition to cancer: a historical overview. Am J Med Genet C Semin Med Genet, 2004. 129C(1): p. 5-22.
[60]
Bishop, D. T., et al., Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst, 2002. 94(12): p. 894-903.
[61]
Balamurugan, A., et al., Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J Am Acad Dermatol, 2011. 65(5 Suppl 1): p. S69-77.
[62]
Bradford, P. T., et al., Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol, 2010. 146(3): p. 265-72.
[63]
Yang, G. B., et al., Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol, 2011. 147(12): p. 1395-402.
[64]
Goggins, W., W. Gao, and H. Tsao, Association between female breast cancer and cutaneous melanoma. Int J Cancer, 2004. 111(5): p. 792-4.
[65]
Liu, H., K. Hemminki, and J. Sundquist, Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family-Cancer Database. J Urol, 2011. 185(6): p. 2045-9.
[66]
Pirani, M., et al., Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol, 2011. 22(8): p. 1845-58.
[67]
Morton, L. M., et al., Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol, 2010. 28(33): p. 4935-44.
[68]
Braam, K. I., et al., Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: a systematic review. Pediatr Blood Cancer, 2012. 58(5): p. 665-74.
[69]
Law, M. H., S. Macgregor, and N. K. Hayward, Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol, 2012. 132(7): p. 1763-74.
[70]
Hansen, C. B., et al., Clinical germline genetic testing for melanoma. Lancet Oncol, 2004. 5(5): p. 314-9.
[71]
Begg, C. B., et al., Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst, 2005. 97(20): p. 1507-15.
[72]
Cachia, A. R., et al., CDKN2A mutation and deletion status in thin and thick primary melanoma. Clin Cancer Res, 2000. 6(9): p. 3511-5.
[73]
Garcia-Borron, J. C., B. L. Sanchez-Laorden, and C. Jimenez-Cervantes, Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res, 2005. 18(6): p. 393-410.
[74]
Ha, T., et al., Defining the quantitative contribution of the melanocortin 1 receptor (MC1R) to variation in pigmentary phenotype. Ann N Y Acad Sci, 2003. 994: p. 339-47.
[75]
Duffy, D. L., et al., Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet, 2004. 13(4): p. 447-61.
[76]
Healy, E., Melanocortin 1 receptor variants, pigmentation, and skin cancer susceptibility. Photodermatol Photoimmunol Photomed, 2004. 20(6): p. 283-8.
[77]
Landi, M. T., et al., MC1R germline variants confer risk for BRAF-mutant melanoma. Science, 2006. 313(5786): p. 521-2.
[78]
Cao, J., et al., MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell, 2013. 51(4): p. 409-22.
[79]
Carey, W. P., Jr., et al., Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer, 1994. 74(12): p. 3118-25.
[80]
Schneider, K. G., Li-Fraumeni Syndrome, in Pagon RA BT, Dolan CR, et al., editors, ed. GeneReviews TM (Internet). 1999, University of Washington: Seattle (WA).
[81]
Martorano, L. M., et al., Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. Int J Dermatol, 2014. 53(6): p. 657-63.
[82]
Said, S., et al., Primary central nervous system amelanotic melanoma in a Hispanic male: Case report. Pol J Radiol, 2014. 79: p. 199-202.
[83]
Khalid, U., et al., Pathogenesis, diagnosis and management of primary melanoma of the colon. World J Surg Oncol, 2011. 9: p. 14.
[84]
Schoneveld, M., et al., Intussusception of the small intestine caused by a primary melanoma? Case Rep Gastroenterol, 2012. 6(1): p. 15-9.
[85]
Haskaraca, M. F., et al., Primary malignant melanoma of the gallbladder: a case report and review of the literature. Case Rep Surg, 2012. 2012: p. 693547.
[86]
Friedman, R. J., D. S. Rigel, and A. W. Kopf, Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin, 1985. 35(3): p. 130-51.
[87]
Grin, C. M., et al., Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol, 1990. 126(6): p. 763-6.
[88]
MacKie, R. M., et al., The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol, 1985. 113(2): p. 167-74.
[89]
Argenziano, G., et al., Seven-point checklist of dermoscopy revisited. Br J Dermatol, 2011. 164(4): p. 785-90.
[90]
MacKie, R. M., Clinical recognition of early invasive malignant melanoma. BMJ, 1990. 301(6759): p. 1005-6.
[91]
Excellence, N. I. f. H. a. C., Referral Guidelines for Suspected Cancer (NICE), N.I.f.H.a.C. Excellence, Editor. 2005: London.
[92]
Grob, J. J. and J. J. Bonerandi, The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol, 1998. 134(1): p. 103-4.
[93]
Gachon, J., et al., First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol, 2005. 141(4): p. 434-8.
[94]
Vestergaard, M. E., et al., Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol, 2008. 159(3): p. 669-76.
[95]
Network, N. C. C., Melanoma. 2004, NCCN Guidelines.
[96]
Bichakjian, C. K., et al., Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol, 2011. 65(5): p. 1032-47.
[97]
Zettersten, E., et al., Prognostic factors in primary cutaneous melanoma. Surg Clin North Am, 2003. 83(1): p. 61-75.
[98]
McGovern, V. J., H. M. Shaw, and G. W. Milton, Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology, 1983. 7(5): p. 673-80.
[99]
Slingluff, C. L., Jr., et al., Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg, 1988. 208(2): p. 150-61.
[100]
Mihm, M. C., Jr., C. G. Clemente, and N. Cascinelli, Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest, 1996. 74(1): p. 43-7.
[101]
Slater, D., Standards and Datasets for Reporting Cancers Dataset for Histological Reporting of Primary Cutaneous Malignant Melanoma and Regional Lymph Nodes, T.R.C.o. Pathologist, Editor. 2014: Carlton House Terrace, London, SW1Y 5AF. p. 1-35.
[102]
Stojadinovic, A., et al., Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg, 2002. 235(1): p. 92-8.
[103]
Koopal, S. A., et al., Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer, 2000. 89(8): p. 1720-5.
[104]
Tanis, P. J., et al., Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol, 2001. 8(3): p. 222-6.
[105]
Scolyer, R. A., et al., Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol, 2008. 25(2): p. 100-11.
[106]
McGovern, V. J., et al., The classification of malignant melanoma and its histologic reporting. Cancer, 1973. 32(6): p. 1446-57.
[107]
Jelfs, P. L., et al., Cutaneous malignant melanoma in Australia, 1989. Med J Aust, 1994. 161(3): p. 182-7.
[108]
Langley RG, F. T., Sober, Balch, CM Houghton AN, Sober AJ, et al., Clinical characteristics in Cutaneous Melanoma. AJ Quality Medical Publishing, 1998: p. 81.
[109]
Price, N. M., A. M. Rywlin, and A. B. Ackerman, Histologic criteria for the diagnosis of superficial spreading malignant melanoma: formulated on the basis of proven metastatic lesions. Cancer, 1976. 38(6): p. 2434-41.
[110]
Liu, V. and M. C. Mihm, Pathology of malignant melanoma. Surg Clin North Am, 2003. 83(1): p. 31-60, v.
[111]
Clark, W. H., Jr., et al., The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res, 1969. 29(3): p. 705-27.
[112]
Clark, W. H., Jr., D. E. Elder, and M. Van Horn, The biologic forms of malignant melanoma. Hum Pathol, 1986. 17(5): p. 443-50.
[113]
Clark, W. H., Jr. and M. C. Mihm, Jr., Lentigo maligna and lentigo-maligna melanoma. Am J Pathol, 1969. 55(1): p. 39-67.
[114]
Weinstock, M. A. and A. J. Sober, The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol, 1987. 116(3): p. 303-10.
[115]
Cohen, L. M., Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol, 1995. 33(6): p. 923-36; quiz 937-40.
[116]
Tannous, Z. S., et al., Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol, 2000. 31(6): p. 705-8.
[117]
Coleman, W. P., 3rd, et al., Acral lentiginous melanoma. Arch Dermatol, 1980. 116(7): p. 773-6.
[118]
Plotnick, H., N. Rachmaninoff, and H. J. VandenBerg, Jr., Polypoid melanoma: a virulent variant of nodular melanoma. Report of three cases and literature review. J Am Acad Dermatol, 1990. 23(5 Pt 1): p. 880-4.
[119]
Mack, E. E. and E. C. Gomez, Neurotropic melanoma. A case report and review of the literature. J Neurooncol, 1992. 13(2): p. 165-71.
[120]
Cheng L, A. A., Desmoplastic Melanoma, Advances in Malignant Melanoma - Clinical and Research Perspectives. 2011.
[121]
Breslow, A., Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg, 1970. 172(5): p. 902-8.
Browse journals by subject